Literature DB >> 21463600

Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities.

Alpa H Gautam1, Gail D Zeevalk.   

Abstract

Loss of dopamine (DA) homeostasis may be a contributing factor to cell damage in Parkinson's disease (PD). Past studies showing deleterious effects of DA on mitochondrial function, however, have been inconsistent raising questions about mitochondria as a downstream target for DA. Issues such as the dopamine species i.e., reduced or oxidized, time of exposure and the effect of major metabolites such as 3,4-dihydrophenylacetic acid (DOPAC) may contribute to the disparate findings. The present study used isolated, lysed rat brain mitochondria to characterize the effects of oxidized or reduced DA and DOPAC on complex activities of the electron transport chain (ETC). Time of exposure and quantitation of reduced or oxidized catachols for DA and DOPAC were monitored for all experiments. Reduced DA and DOPAC with or without a 30min preincubation had no affect on NADH oxidase activity which monitors the activities of complexes I, III and IV. Complex II activity was inhibited by reduced DA (≥500μM), but not by reduced DOPAC and was significantly attenuated by SOD suggesting reactive oxygen species involvement. In contrast, fully oxidized DA and DOPAC dose dependently inhibited NADH oxidase, complex I and complex III activities with IC(50s) in the 50-200μM range. No preincubation was required for inhibition with the catechols when they were fully oxidized. Oxidized DA inhibited complex I only when exposure occurred during stimulated electron flow, suggesting covalent binding of quinones to proteins within active sites of the complex. In intact, well coupled mitochondria, extramitochondrial DA was shown to access the mitochondrial matrix in a dose, time and energy-dependent fashion. The findings suggest that many of the reported inconsistencies with regards to the effects of DA and DOPAC on ETC function can be attributed to the oxidized state of the catechol at the time of exposure. In addition, the findings provide possible downstream targets for DA that could contribute to the vulnerability of dopaminergic neurons in PD.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463600      PMCID: PMC3108181          DOI: 10.1016/j.bbabio.2011.03.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  30 in total

1.  Abnormalities of the electron transport chain in idiopathic Parkinson's disease.

Authors:  W D Parker; S J Boyson; J K Parks
Journal:  Ann Neurol       Date:  1989-12       Impact factor: 10.422

2.  Mitochondrial complex I deficiency in Parkinson's disease.

Authors:  A H Schapira; J M Cooper; D Dexter; J B Clark; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1990-03       Impact factor: 5.372

3.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

Authors:  D G Graham
Journal:  Mol Pharmacol       Date:  1978-07       Impact factor: 4.436

4.  The metabolism of rat brain mitochondria. Preparation and characterization.

Authors:  J B Clark; W J Nicklas
Journal:  J Biol Chem       Date:  1970-09-25       Impact factor: 5.157

5.  An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria.

Authors:  M A Birch-Machin; H L Briggs; A A Saborido; L A Bindoff; D M Turnbull
Journal:  Biochem Med Metab Biol       Date:  1994-02

6.  An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease.

Authors:  Y Mizuno; S Matuda; H Yoshino; H Mori; N Hattori; S Ikebe
Journal:  Ann Neurol       Date:  1994-02       Impact factor: 10.422

7.  Decreased activities of ubiquinol:ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c:oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin[c-lactam]-induced methylmalonic aciduria.

Authors:  S Krahenbuhl; M Chang; E P Brass; C L Hoppel
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

8.  Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione.

Authors:  T G Hastings; M J Zigmond
Journal:  J Neurochem       Date:  1994-09       Impact factor: 5.372

9.  Mechanistic studies on tyrosinase-catalysed oxidative decarboxylation of 3,4-dihydroxymandelic acid.

Authors:  M Sugumaran; H Dali; V Semensi
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

10.  Dopamine neurotoxicity: inhibition of mitochondrial respiration.

Authors:  D Ben-Shachar; R Zuk; Y Glinka
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

View more
  12 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 2.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

Review 3.  The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-01-20       Impact factor: 5.590

4.  Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.

Authors:  Sudhakar Raja Subramaniam; Laurent Vergnes; Nicholas R Franich; Karen Reue; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2014-07-10       Impact factor: 5.996

Review 5.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

Review 6.  Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities.

Authors:  Juan I Sbodio; Solomon H Snyder; Bindu D Paul
Journal:  Antioxid Redox Signal       Date:  2018-05-04       Impact factor: 8.401

Review 7.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Sudhakar Raja Subramaniam; Marie-Francoise Chesselet
Journal:  Prog Neurobiol       Date:  2013-04-30       Impact factor: 11.685

8.  L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and striatum of the rat.

Authors:  Zachary D Brodnik; Manda Double; Rodrigo A España; George E Jaskiw
Journal:  Neuropharmacology       Date:  2017-05-29       Impact factor: 5.250

Review 9.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

Review 10.  Oxidative Stress and Neuroinflammation Potentiate Each Other to Promote Progression of Dopamine Neurodegeneration.

Authors:  Jingyi He; Guofu Zhu; Guoqing Wang; Feng Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-07-03       Impact factor: 7.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.